DocInsight belongs to a broader market transformation: the shift from survey-led HCP research — episodic, self-reported, retrospective — to always-on clinician-behaviour intelligence drawn from platforms where clinicians actually work. This shift is consequential because it changes both the quality and the timeliness of the intelligence available to companies building healthcare products.
From Surveys to Behavioural Insight
Traditional HCP insight relied heavily on established research methods: surveys (what physicians say they think, conducted periodically), advisory boards (what a small expert group recommends, usually 6-12 physicians), field-force feedback (what sales representatives observe during visits), claims data (what was prescribed and billed, captured months after the clinical decision), and conference engagement (which sessions physicians attended, which content they downloaded).
Each method remains useful. None is sufficient alone. Surveys capture stated preferences — which decades of research show differ systematically from actual behaviour. Advisory boards capture expert opinion — which may not represent typical clinical practice across different settings, specialties, and career stages. Field-force feedback captures individual observations — filtered through the sales relationship. Claims data captures what happened after the decision — not what the clinician was thinking, searching for, or uncertain about during the decision itself.
Platforms like Doximity sit closer to real clinician workflow — capturing what physicians actually search for, what drug information they access, what clinical AI answers they engage with, what documentation they generate, what PeerCheck-certified content they trust, and which workflow features they return to daily. This creates a different class of signal: not what clinicians say they do in a research context, but what they actually do during their working day.
Doximity's Structural Advantage
Doximity reaches 85% of US physicians — over 3 million members. Its Q4 FY2026 engagement hit 800,000+ active prescribers using workflow tools, with nearly half using clinical AI. The Aledade partnership places Ask and Scribe inside value-based care workflows across thousands of independent practices. The Pathway Medical acquisition ($63 million) added 3,200+ drug monographs. PeerCheck provides physician review from 10,000+ medical experts. Full-year revenue was $644.9 million with record quarterly free cash flow of $107 million.
DocInsight sits on top of this infrastructure — turning the behavioural data generated by daily physician engagement into strategic intelligence for life-sciences partners. The offering is described as insights, analytics, and strategy built with clients, using Doximity's physician engagement data, data science capability, and AI-first infrastructure.
Why DocInsight Is Strategically Logical
If a platform knows what clinicians read, ask, document, search, prescribe, reference, and engage with — across multiple workflow touchpoints and at population scale — it can inform life-sciences strategy in ways that traditional research cannot. Which clinical topics generate the most engagement and repeated queries (suggesting educational gaps or guideline complexity). Which drug information is most frequently accessed and re-accessed (suggesting prescribing uncertainty or monitoring confusion). How clinical AI adoption patterns vary by specialty, geography, and practice type (informing product targeting and go-to-market strategy). What physician verification behaviours look like when using AI-generated answers (informing trust-building strategies and product UX). Where workflow friction creates opportunities for new tools, better content, or improved integration (informing product development priorities).
The intelligence is continuous, behavioural, multi-dimensional, and at scale. Surveys cannot match this.
Why UK Healthtech Needs a Different Intelligence Layer
For UK healthtech firms and life-sciences organisations, the intelligence question is not simply "which doctors are engaging with our content?" It is a more complex set of UK-specific questions that US physician engagement data cannot answer.
What does the NHS require for procurement, governance, and clinical safety? What MHRA classification applies to our product's intended use — and what changes if we modify our claims? What guideline sources must our clinical content align with — NICE, CKS, SmPC/eMC, MHRA drug safety updates, SIGN? What claims are safe under UK medical device advertising regulations? What clinical safety evidence do we need for DCB 0129/0160? What DTAC criteria must we satisfy — and what happens if we do not? What do UK clinicians actually need from our product — as opposed to what our US product team assumes based on US physician behaviour?
These questions require UK-specific intelligence: understanding of UK guidelines, UK regulatory frameworks, UK procurement processes, UK clinician trust dynamics, and UK clinical practice patterns. US engagement data — however comprehensive — does not provide this.
iatroX Insights as UK Clinical Intelligence
iatroX Insights provides this UK-specific intelligence layer. Not HCP marketing. Not promotional targeting. Not physician-level engagement analytics for sales optimisation. Clinical-intent analysis, regulatory advisory, clinician validation, and adoption intelligence for partners building healthcare products for UK clinicians and UK health systems.
The division supports digital-health companies (UK market-entry readiness, product validation, clinical safety case development), NHS innovation teams (guideline implementation assessment, clinical AI evaluation, adoption-barrier analysis), medical publishers (educational content gap analysis, clinical question mapping, topic prioritisation), life-sciences medical affairs teams (UK clinician behaviour patterns, evidence strategy, educational need identification, therapeutic-area intelligence), and academic researchers (clinical information needs research, knowledge translation studies, unmet-need mapping).
The distinction from DocInsight is deliberate and structural: iatroX Insights is UK clinical intelligence — not US physician engagement marketing. The value is understanding what UK clinicians need, where UK guidance creates friction, what UK regulation requires, and how to build products that UK clinicians will trust and UK health systems will adopt.
Commission a UK clinical-intelligence or market-entry report from iatroX Insights →